vs
Side-by-side financial comparison of American Express (AXP) and CollPlant Biotechnologies Ltd (CLGN). Click either name above to swap in a different company.
American Express is the larger business by last-quarter revenue ($18.9M vs $10.2M, roughly 1.9× CollPlant Biotechnologies Ltd). CollPlant Biotechnologies Ltd runs the higher net margin — 56.6% vs 15.7%, a 40.9% gap on every dollar of revenue. On growth, CollPlant Biotechnologies Ltd posted the faster year-over-year revenue change (15330.3% vs 11.4%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.
AXP vs CLGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $10.2M |
| Net Profit | $3.0M | $5.8M |
| Gross Margin | — | 94.0% |
| Operating Margin | — | 55.7% |
| Net Margin | 15.7% | 56.6% |
| Revenue YoY | 11.4% | 15330.3% |
| Net Profit YoY | 15.0% | 234.5% |
| EPS (diluted) | — | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | — | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $10.3B | — | ||
| Q1 25 | $9.6B | — | ||
| Q4 24 | $10.0B | — | ||
| Q3 24 | $9.7B | — | ||
| Q2 24 | $9.8B | — |
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $2.9B | — | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $3.0B | — |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | — | ||
| Q3 25 | 36.7% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 34.6% | — | ||
| Q4 24 | 27.7% | — | ||
| Q3 24 | 33.0% | — | ||
| Q2 24 | 38.6% | — |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 27.9% | — | ||
| Q2 25 | 28.0% | — | ||
| Q1 25 | 26.8% | — | ||
| Q4 24 | 21.8% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 30.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | — | ||
| Q3 25 | $4.14 | — | ||
| Q2 25 | $4.08 | — | ||
| Q1 25 | $3.64 | — | ||
| Q4 24 | $3.04 | — | ||
| Q3 24 | $3.49 | — | ||
| Q2 24 | $4.15 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $22.3M |
| Total DebtLower is stronger | $60.4M | — |
| Stockholders' EquityBook value | $34.0M | $36.0M |
| Total Assets | $308.9M | $41.6M |
| Debt / EquityLower = less leverage | 1.78× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $197.0M | — | ||
| Q1 25 | $261.0M | — | ||
| Q4 24 | $221.0M | — | ||
| Q3 24 | $120.0M | — | ||
| Q2 24 | $188.0M | — |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | — | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | — | ||
| Q3 25 | $32.4B | — | ||
| Q2 25 | $32.3B | — | ||
| Q1 25 | $31.2B | — | ||
| Q4 24 | $30.3B | — | ||
| Q3 24 | $29.7B | — | ||
| Q2 24 | $29.5B | — |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | — | ||
| Q3 25 | $297.6B | — | ||
| Q2 25 | $295.6B | — | ||
| Q1 25 | $282.2B | — | ||
| Q4 24 | $271.5B | — | ||
| Q3 24 | $271.0B | — | ||
| Q2 24 | $272.2B | — |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
CLGN
Segment breakdown not available.
